Prostate Cancer
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetanin Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)who Progressed on Androgen Receptor (AR) Pathway Inhibition (PRESERVE-006)
- Details
ClinicalTrials.gov ID:
NCT05682443
Diagnosis Type:
NA
USOR Number:
- Address
,
P: